Trials / NCT06952842
Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation
Recruiting now Phase 1 / Phase 2 Gene editing, Gene therapy
- Sponsor
- Chigenovo Co., Ltd
- Treatment
- ZVS203e
- Gene
- RHO
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 18 participants
- Started
- 2025-08-04
- Main results expected
- 2030-06-18
- Results posted
- Not yet
- Record last updated
- 2026-06-17
What the study is testing
This trial employs a single-arm, open-label seamless Phase I/II design, consisting of two stages: Phase I dose exploration and Phase II dose expansion.The primary objective of this trial is to evaluate the safety, tolerability, and efficacy of subretinal injection of ZVS203e solution.
Where it runs
China (1)
- Peking University Third Hospital, Beijing, Beijing Municipality (recruiting now)